What is Hemosep?

We are delighted to release the next generation of Hemosep - our innovative cell salvage system.

The Hemosep cell salvage system is designed to recover blood loss during cardiac and other surgical specialities, providing a concentration of all cell species for transfusion back to the patient.

It offers exciting new opportunities for health services to improve patient outcomes and reduce costs. 

More info

 

Why is Hemosep different?

Hemosep is the result of a partnership of Advancis Surgical and Professor Terence Gourlay at the University of Strathclyde. Clinical trials have already been undertaken at University Hospital in Ankara, Turkey and Guy’s and St Thomas’ Hospital, London. 

Professor Terence Gourlay, says: “The introduction of Hemosep to the medical device field will make a significant difference to people’s lives and greatly reduce the cost and risks associated with blood transfusions. The technology has distinct advantages over traditional techniques which are not only costly but technically challenging and involve the use of a complex centrifuge and pumping apparatus by specialist technicians.”

Watch the BBC’s report, including their interview with Prof. Grourlay, on Hemosep

Professor Serdar Gunaydin, University of Kirkkale, Turkey,  says: “The Hemosep technology has produced impressive results, it is the easiest method we have ever used. There is no interference with the on-going operation and product is ready following a very short processing time. We believe this new technology will be one of the essential components of routine heart surgery in the near future.”

Stephen Cotton, Brightwake’s Managing Director, said: “We’re delighted to be able to make this announcement, which comes after considerable shared effort to develop this exciting product. We hope that this success will be the first of many through our collaboration with the University of Strathclyde.”

More info